Juli M Bollinger1, Ann Eno2, Shanti Seaman3, Diane Brown3, Sarah E Van Pilsum Rasmussen2, Aaron A R Tobian3,4,5, Dorry L Segev2,3,6, Christine M Durand3, Jeremy Sugarman1,3. 1. Berman Institute of Bioethics, Johns Hopkins University, Baltimore, Maryland. 2. Department of Surgery, Johns Hopkins University School of Medicine, Baltimore, Maryland. 3. Department of Medicine, Johns Hopkins School of Medicine, Baltimore, Maryland. 4. Department of Epidemiology, Johns Hopkins University School of Public Health, Baltimore, Maryland. 5. Department of Pathology, The Johns Hopkins Hospital, Baltimore, Maryland. 6. School of Nursing, Johns Hopkins University, Baltimore, Maryland.
Abstract
BACKGROUND: HIV+ to HIV+ solid organ transplants in the United States are now legally permitted. Currently, these transplants must adhere to the HIV Organ Policy Equity (HOPE) Act Safeguards and Research Criteria that require the provision of an independent recipient advocate, a novel requirement for solid organ transplant programs. The objective of this study was to understand the experiences of the first advocates serving in this role. METHODS: We conducted semi-structured interviews with 15 HOPE independent recipient advocates (HIRAs) from 12 institutions. RESULTS: All HIRAs had a professional degree and experience in transplantation or infectious diseases. HIRAs' encounters with potential recipients varied in length, modality, and timing. The newness of the role and the lack of guidance were associated with unease among some HIRAs. Some questioned whether their role was redundant to others involved in transplantation and research since some potential recipients experienced informational fatigue. CONCLUSIONS: HOPE independent recipient advocates are ensuring the voluntariness of potential participants' decision to accept an HIV-infected organ. Many suggested additional guidance would be helpful and alleviate unease. Concerns about potential role redundancy raise the question of whether the HIRA requirement may be inadvertently increasing burden for potential recipients. Future work that captures the experiences of potential recipients is warranted.
BACKGROUND:HIV+ to HIV+ solid organ transplants in the United States are now legally permitted. Currently, these transplants must adhere to the HIV Organ Policy Equity (HOPE) Act Safeguards and Research Criteria that require the provision of an independent recipient advocate, a novel requirement for solid organ transplant programs. The objective of this study was to understand the experiences of the first advocates serving in this role. METHODS: We conducted semi-structured interviews with 15 HOPE independent recipient advocates (HIRAs) from 12 institutions. RESULTS: All HIRAs had a professional degree and experience in transplantation or infectious diseases. HIRAs' encounters with potential recipients varied in length, modality, and timing. The newness of the role and the lack of guidance were associated with unease among some HIRAs. Some questioned whether their role was redundant to others involved in transplantation and research since some potential recipients experienced informational fatigue. CONCLUSIONS: HOPE independent recipient advocates are ensuring the voluntariness of potential participants' decision to accept an HIV-infected organ. Many suggested additional guidance would be helpful and alleviate unease. Concerns about potential role redundancy raise the question of whether the HIRA requirement may be inadvertently increasing burden for potential recipients. Future work that captures the experiences of potential recipients is warranted.
Keywords:
acquired immunodeficiency syndrome; care delivery; ethics; infection and infectious agents; organ procurement and transplantation network; patient safety; quality of care; viral: human immunodeficiency virus
Authors: Jayme E Locke; Nathan T James; Roslyn B Mannon; Shikha G Mehta; Peter G Pappas; John W Baddley; Niraj M Desai; Robert A Montgomery; Dorry L Segev Journal: Transplantation Date: 2014-02-27 Impact factor: 4.939
Authors: Peter G Stock; Burc Barin; Barbara Murphy; Douglas Hanto; Jorge M Diego; Jimmy Light; Charles Davis; Emily Blumberg; David Simon; Aruna Subramanian; J Michael Millis; G Marshall Lyon; Kenneth Brayman; Doug Slakey; Ron Shapiro; Joseph Melancon; Jeffrey M Jacobson; Valentina Stosor; Jean L Olson; Donald M Stablein; Michelle E Roland Journal: N Engl J Med Date: 2010-11-18 Impact factor: 91.245
Authors: J Steel; A Dunlavy; M Friday; K Kingsley; D Brower; M Unruh; H Tan; R Shapiro; M Peltz; M Hardoby; C McCloskey; M Sturdevant; A Humar Journal: Am J Transplant Date: 2012-05-01 Impact factor: 8.086
Authors: Shanti Seaman; Diane Brown; Ann Eno; Sile Yu; Allan B Massie; Aaron A R Tobian; Christine M Durand; Dorry L Segev; Albert W Wu; Jeremy Sugarman Journal: J Patient Rep Outcomes Date: 2021-03-18
Authors: Sarah E Van Pilsum Rasmussen; Shanti Seaman; Morgan A Johnson; Karen Vanterpool; Diane M Brown; Aaron A R Tobian; Timothy Pruett; Varvara Kirchner; Faith E Fletcher; Burke Smith; Sonya Trinh; Dorry L Segev; Christine M Durand; Jeremy Sugarman Journal: Transplant Direct Date: 2021-08-06